Skip to main content

Advertisement

SpringerLink
Log in

Der Tumormarker Serotonin

The tumor marker serotonin

  • Übersichten: Arbeitsmedizin – Umweltmedizin
  • Published:
Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie Aims and scope Submit manuscript

Zusammenfassung

Die vorliegende Übersicht zum Tumormarker Serotonin wird im Rahmen der Serie „Tumormarker“ des Zentralblatts für Arbeitsmedizin, Arbeitsschutz und Ergonomie publiziert, die sich mit dem immer häufigeren Gebrauch der Bestimmung von spezifischen Markern bei sog. Manager-Vorsorgen und Check-up-Untersuchungen beschäftigt. Serotonin eignet sich grundsätzlich nicht für solche Vorsorgen, sondern ist ein Marker zur Therapie‑, Verlaufs- und Rezidivkontrolle von neuroendokrinen Tumoren. Hier zeigt dieser eine hohe Sensitivität und Spezifität, wobei der Marker aber keinesfalls als Screening-Parameter zur Frühdiagnostik eingesetzt werden soll.

Abstract

The present overview on the tumor marker serotonin is part of the series on tumor markers of the Zentralblatt für Arbeitsmedizin, Arbeitsschutz und Ergonomie, which deals with the increasing use of the determination of specific markers in so-called manager preventive and check-up examinations. In principle, serotonin is not suitable for such precautionary measures but is a marker for the treatment, progression and recurrence control of neuroendocrine tumors. In this aspect it shows a high sensitivity and specificity but the marker should not be used as a screening parameter for early diagnosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Gerber A, Jäger M, Groneberg DA (2017) Editorial: Tumormarker in der Vorsorge? Zentralbl Arbeitsmed Arbeitsschutz Ergonomie 67(4):199–200

    Article  CAS  Google Scholar 

  2. Tsaur I, Thurn K, Juengel E, Oppermann E, Nelson K, Thomas C, Bartsch G, Oremek GM, Haferkamp A, Rubenwolf P, Blaheta RA (2016) Evaluation of TKLTL1 as a biomarker in serum of prostate cancer patients. Cent European J Urol 69(3):247–251

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Zulauf N, Oremek GM, Groneberg D (2016) Bone marker in women with breast cancer. Curr Biomarkers 6:61–68

    Article  CAS  Google Scholar 

  4. Onkologie L (2018) S2k-Leitlinie Neuroendokrine Tumoren. Langversion März 2018 AWMF-Register-Nummer: 021/26

    Google Scholar 

  5. Bundesärztekammer (2014) Neufassung der „Richtlinie der Bundesärztekammer zur Qualitätssicherung laboratoriumsmedizinischer Untersuchungen – Rili-BÄK“. Dtsch Arztebl 111:A1583–A1618

    Google Scholar 

  6. Duffy MJ, Sturgeon CM, Sölétormos G, Barak V, Molina R, Hayes DF, Diamandis EP, Bossuyt PM (2015) Validation of new cancer biomarkers: a position statement from the European group on tumor markers. Clin Chem 61(6):809–820

    Article  CAS  PubMed  Google Scholar 

  7. Hölzel D, Schubert-Fritschle G, Schmidt M, Eckel R, Engel J (2016) Klinisch-epidemiologische Krebsregistrierung in Deutschland. Onkologe 22:61–78

    Article  Google Scholar 

  8. In-Vitro-Diagnostika EPURÜ (2009) Richtlinie 98/79/EG des Europäischen Parlaments und des Rates über In-vitro-Diagnostika

    Google Scholar 

  9. Institut RK (2016) Bericht zum Krebsgeschehen in Deutschland 2016 (ICD-10 C15–26)

    Google Scholar 

  10. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O’Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK (2017) The north American Neuroendocrine Tumor Society Consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas 46(6):707–714

    Article  PubMed  PubMed Central  Google Scholar 

  11. Budnik LT, Adam B, Albin M, Banelli B, Baur X, Belpoggi F, Bolognesi C, Broberg K, Gustavsson P, Göen T, Fischer A, Jarosinska D, Manservisi F, O’Kennedy R, Øvrevik J, Paunovic E, Ritz B, Scheepers PTJ, Schlünssen V, Schwarzenbach H, Schwarze PE, Sheils O, Sigsgaard T, Van Damme K, Casteleyn L (2018) Diagnosis, monitoring and prevention of exposure-related non-communicable diseases in the living and working environment: DiMoPEx-project is designed to determine the impacts of environmental exposure on human health. J Occup Med Toxicol 13:6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Schulte HM, Jacobeit J (2013) Lexikon der Medizinischen Laboratoriumsdiagnostik: Serotonin. Springer, Berlin, Heidelberg

    Google Scholar 

  13. Kunz PL (2015) Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol 33:1855–1863

    Article  CAS  PubMed  Google Scholar 

  14. Bergsland EK (2013) The evolving landscape of neuroendocrine tumors. Semin Oncol 40:4–22

    Article  PubMed  Google Scholar 

  15. Klimstra DS, Modlin IR, Coppola D et al (2010) The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 39:707–712

    Article  PubMed  Google Scholar 

  16. Scherübl H, Streller B, Stabenow R, Herbst H, Höpfner M, Schwertner C, Steinberg J, Eick J, Ring W, Tiwari K, Zappe SM (2013) Clinically detected gastroenteropancreatic neuroendocrine tumors are on the rise: epidemiological changes in Germany. World J Gastroenterol 19(47):9012–9019

    Article  PubMed  PubMed Central  Google Scholar 

  17. Klöppel G, Perren A, Heitz PU (2004) The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 1014:13–27

    Article  PubMed  Google Scholar 

  18. Perren A, Couvelard A, Scoazec JY, Costa F, Borbath I, Delle Fave G, Gorbounova V, Gross D, Grossma A, Jense RT, Kulke M, Oeberg K, Rindi G, Sorbye H, Welin S Antibes Consensus Conference Participants (2017) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: pathology: diagnosis and prognostic stratification. Neuroendocrinology 105(3):196–200

    Article  CAS  PubMed  Google Scholar 

  19. Hassan MM, Phan A, Li D, Dagohoy CG, Leary C, Yao JC (2008) Family history of cancer and associated risk of developing neuroendocrine tumors: a case-control study. Cancer Epidemiol Biomarkers Prev 17(4):959–965

    Article  PubMed  Google Scholar 

  20. Du Y, Ter-Minassian M, Brais L, Brooks N, Waldron A, Chan JA, Lin X, Kraft P, Christiani DC, Kulke MH (2016) Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study. Endocr Relat Cancer 23(8):587–594

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Rinzivillo M, Capurso G, Campana D, Fazio N, Panzuto F, Spada F, Cicchese N, Partelli S, Tomassetti P, Falconi M, Delle Fave G (2016) Risk and protective factors for small intestine neuroendocrine tumors: a prospective case-control study. Neuroendocrinology 103(5):531–537

    Article  CAS  PubMed  Google Scholar 

  22. Jung YS, Yun KE, Chang Y, Ryu S, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Park DI (2014) Risk factors associated with rectal neuroendocrine tumors: a cross-sectional study. Cancer Epidemiol Biomarkers Prev 23(7):1406–1413

    Article  CAS  PubMed  Google Scholar 

  23. Romaniuk А, Lyndin M, Sikora V, Lyndina Y, Romaniuk S, Sikora K (2017) Heavy metals effect on breast cancer progression. J Occup Med Toxicol 12:32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Westermann C, Wendeler D, Nienhaus A (2018) Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents. J Occup Med Toxicol 13:16

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sarrouilhe D, Mesnil M (2018) Serotonin and human cancer: a critical view. Biochimie. https://doi.org/10.1016/j.biochi.2018.06.016

    Article  PubMed  Google Scholar 

  26. Modlin IM, Bodei L, Kidd M (2016) Neuroendocrine tumor biomarkers: from monoanalytes to transcripts and algorithms. Best Pract Res Clin Endocrinol Metab 30(1):59–77

    Article  CAS  PubMed  Google Scholar 

  27. Sarrouilhe D, Clarhaut J, Defamie N, Mesnil M (2015) Serotonin and cancer: what is the link? Curr Mol Med 15(1):62–77

    Article  CAS  PubMed  Google Scholar 

  28. Joseph L, Gomes MP, Al Solaiman F, John StJ, Ozaki A, Raju M, Dhariwal M, Kim ES (2015) External validation of the HIT Expert Probability (HEP) score. Thromb Haemost 113(3):633–640

    Article  PubMed  Google Scholar 

  29. Albert PR, Benkelfat C, Descarries L (2012) The neurobiology of depression—revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci 367(1601):2378–2381

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Shajib MS, Khan WI (2015) The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf) 213(3):561–574

    Article  CAS  Google Scholar 

  31. Heinrich E, Trojan L, Friedrich D, Voss M, Weiss C, Michel MS, Grobholz R (2011) Neuroendocrine tumor cells in prostate cancer: evaluation of the neurosecretory products serotonin, bombesin, and gastrin—impact on angiogenesis and clinical follow-up. Prostate 71(16):1752–1758

    Article  CAS  PubMed  Google Scholar 

  32. Fröbe A, Čičin-Šain L, Jones G, Soldič Ž, Lukač J, Bolanča A, Kusič Z (2014) Plasma free serotonin as a marker for early detection of breast cancer recurrence. Anticancer Res 34(3):1167–1169

    PubMed  Google Scholar 

  33. Abdel-Razik A, Elhelaly R, Elzehery R, El-Diasty A, Abed S, Elhammady D, Tawfik A (2016) Could serotonin be a potential marker for hepatocellular carcinoma? A prospective single-center observational study. Eur J Gastroenterol Hepatol 28(5):599–605

    Article  CAS  PubMed  Google Scholar 

  34. Baldo BA (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92(8):2457–2473

    Article  CAS  PubMed  Google Scholar 

  35. Cheng S, Tollefson D, He G, Li Y, Guo H, Chai S, Gao F, Gao F, Han G, Ren L, Ren Y, Li J, Wang L, Varma JK, Hu D, Fan H, Zhao F, Bloss E, Wang Y, Rao CY (2018) Evaluating a framework for tuberculosis screening among healthcare workers in clinical settings, Inner Mongolia, China. J Occup Med Toxicol 13:11

    Article  PubMed  PubMed Central  Google Scholar 

  36. Mastrangelo G, Carta A, Arici C, Pavanello S, Porru S (2017) An etiologic prediction model incorporating biomarkers to predict the bladder cancer risk associated with occupational exposure to aromatic amines: a pilot study. J Occup Med Toxicol 12:23

    Article  PubMed  PubMed Central  Google Scholar 

  37. Eisenhawer C, Felten MK, Hager T, Gronostayskiy M, Bruners P, Tannapfel A, Kraus T (2017) Migrating pleural plaque in a patient with asbestos induced pleural disease: a case report. J Occup Med Toxicol 12:25

    Article  PubMed  PubMed Central  Google Scholar 

  38. Fuchs S, Parthier K, Wienke A, Mau W, Klement A (2017) Fostering needs assessment and access to medical rehabilitation for patients with chronic disease and endangered work ability: protocol of a multilevel evaluation on the effectiveness and efficacy of a CME intervention for general practitioners. J Occup Med Toxicol 12:21

    Article  PubMed  PubMed Central  Google Scholar 

  39. Alami YZ, Ghanim BT, Zyoud SH (2018) Epworth sleepiness scale in medical residents: quality of sleep and its relationship to quality of life. J Occup Med Toxicol 13:21

    Article  PubMed  PubMed Central  Google Scholar 

  40. Daba Wami S, Chercos DH, Dessie A, Gizaw Z, Getachew A, Hambisa T, Guadu T, Getachew D, Destaw B (2018) Cotton dust exposure and self-reported respiratory symptoms among textile factory workers in Northwest Ethiopia: a comparative cross-sectional study. J Occup Med Toxicol 13:13

    Article  PubMed  PubMed Central  Google Scholar 

  41. Frohlich MJ, Kroidl RF, Welte T (2018) Oxygen Consumption (V’O2) and physical Strainas measured by the occupational activity of cleaning personnel. J Occup Med Toxicol 13:4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. Labordiagnostik, Institut für Arbeitsmedizin, Sozialmedizin und Umweltmedizin, Goethe Universität Frankfurt, Theodor Stern Kai 7, Haus 9a, 60590, Frankfurt am Main, Deutschland

    K. Passek, N. Zulauf, M. H. Bendels, M. Braun &  G. M. Oremek

Authors
  1. K. Passek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Zulauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. H. Bendels
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Braun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. M. Oremek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. M. Oremek.

Ethics declarations

Interessenkonflikt

K. Passek, N. Zulauf, M.H. Bendels, M. Braun und G.M. Oremek geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Passek, K., Zulauf, N., Bendels, M.H. et al. Der Tumormarker Serotonin. Zbl Arbeitsmed 69, 306–309 (2019). https://doi.org/10.1007/s40664-018-0319-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40664-018-0319-0

Schlüsselwörter

Keywords

Search

Navigation